Table 3.
Peptide | Sequence | Acetyl | Methyl |
---|---|---|---|
In vitro acetylation | |||
1–17 | SGRGKGGKGLGKGGAKR | 5 | 1 |
1–17 | SGRGKGGKGLGKGGAKR | 5 | 2 |
4–17 | GKGGKGLGKGGAKR | 4 | 0 |
4–17 | GKGGKGLGKGGAKR | 4 | 1 |
In vitro propionylation | |||
1–17 | SGRGKGGKGLGKGGAKR | 4 | 0 |
1–17 | SGRGKGGKGLGKGGAKR | 3 | 0 |
1–17 | SGRGKGGKGLGKGGAKR | 3 | 1 |
1–17 | SGRGKGGKGLGKGGAKR | 2 | 0 |
1–17 | SGRGKGGKGLGKGGAKR | 2 | 1 |
1–17 | SGRGKGGKGLGKGGAKR | 1 | 0 |
1–17 | SGRGKGGKGLGKGGAKR | 1 | 1 |
1–17 | SGRGKGGKGLGKGGAKR | 1 | 2 |
1–17 | SGRGKGGKGLGKGGAKR | 0 | 0 |
4–17 | GKGGKGLGKGGAKR | 4 | 0 |
4–17 | GKGGKGLGKGGAKR | 3 | 0 |
4–17 | GKGGKGLGKGGAKR | 2 | 0 |
4–17 | GKGGKGLGKGGAKR | 1 | 0 |
4–17 | GKGGKGLGKGGAKR | 0 | 0 |
4–17 | GKGGKGLGKGGAKR | 0 | 1 |
Precursors were sequenced by targeted PRM to determine the sites of modification reported in supplemental Table S2.